The Experience Matters. Let us show you why. Contact us today.
Dr. W. Mark Riddle, M.D explores signal detection and signal management in Pharmacovigilance.
What information should be examined in the study and work up of ADRs to determine whether the reaction is likely due to the drug or not.
Bart Cobert reviews the changes and updates happening with UK and EMA inspections.
We participate in safety reporting not only because it is required by law, but because we are HCPs whose first duty is always to protect the patient.
An update on the status of Brexit and the EMA move to Amsterdam.
Bart Cobert addresses confusing areas in Drug Safety and Pharmacovigilance including Brexit, basic terminology, date formatting and others.
Pharmacovigilance expert Bart Cobert examines the issues associated with language translation in PV and drug safety.
Bart Cobert highlights the ongoing saga with EMA and Brexit. In this post, he elaborates on the lack of a current Brexit deal between the EU and the UK.
Nurses today are in an optimal position to help pharma companies. Dr. Adele Mueller shares how empowering nurses empowers patients.
Another update from Bart Cobert regarding the ongoing Brexit saga.